Isopropyl-D-glucopyranoside derivatives, production method and uses thereof
Isopropyl-D-glucopyranoside derivatives address the lack of effective neural regeneration drugs by traversing the blood-brain barrier to repair central and peripheral nerves, enhancing nerve regeneration in brain tissue models.
Patent Information
- Application Number
- JP2024547816
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-10-25
- Filing Date
- 2022-10-25
- Publication Date
- 2024-11-06
AI Technical Summary
Current treatments for neurological injuries, such as traumatic brain injury, lack effective drugs that can promote neural regeneration, and existing drugs struggle to cross the blood-brain barrier.
Development of isopropyl-D-glucopyranoside derivatives that can traverse the olfactory and trigeminal nerve pathways to reach the cerebrum, facilitating repair of both central and peripheral nerves by promoting nerve regeneration.
The isopropyl-D-glucopyranoside derivatives effectively cross the blood-brain barrier, repairing central and peripheral nerves, including cranial nerves, and promoting neural regeneration in both two-dimensional and three-dimensional brain tissue models.
Smart Images

Figure 2024541121000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention provides isopropyl-D-glucopyranoside derivatives and methods for their synthesis, as well as the use of the isopropyl-D-glucopyranoside derivatives for promoting nerve repair. [Background technology]
[0002] Currently, approximately 70 million people worldwide suffer from neurological injuries such as traumatic brain injury (TBI) every year. Common treatments include non-invasive treatments such as physical therapy, hyperbaric oxygen therapy, transcranial magnetic stimulation, and transcranial direct current stimulation, which can improve depression and cognitive function after TBI. However, there are currently no effective drugs that can promote neuronal regeneration after brain injury.
[0003] Traumatic brain injury is an injury caused by an external force impacting the brain, and there are approximately 70 million diagnosed cases worldwide each year. Traumatic brain injury damages the cranial nerves, resulting in a loss of behavioral or cognitive function in patients. Because it is difficult for the central nervous system to regenerate or recover once damaged, current medicine does not have a treatment that effectively promotes nerve regeneration for traumatic brain injury. In addition, patients with brain trauma often develop lesions in the brain after a certain period of time, or develop neurodegenerative diseases in the future. Therefore, the solution in treatment is to use drugs that promote the regeneration of the cranial nerves as soon as possible after brain injury.
[0004] In addition, in the selection of therapeutic drugs, because the cerebrum has the blood-brain barrier, common drugs cannot freely pass through the blood-brain barrier to reach an effective dose, so the administration of effective drugs is an important issue in treating brain diseases. Summary of the Invention [Problem to be solved by the invention]
[0005] In view of the above, there is currently a great need for the development of drugs capable of treating neurological damage, as well as a great need for administration regimes that can cross the blood-brain barrier. [Means for solving the problem]
[0006] The purpose of the Summary of the Invention is to provide an overview of the contents of the present disclosure so that the reader can have a basic understanding of the contents of the present disclosure. This Summary of the Invention is not a complete summary of the contents of the present disclosure, and is not intended to point out the key / major assemblies of the embodiments of the present invention, or to define the scope of the present invention.
[0007] The nervous system of the human body is divided into central nervous system and peripheral nervous system, both of which are composed of neurons.Trigeminal nerve is a cranial nerve of peripheral nerve, and is connected to pons (central nerve).Therefore, the compound of the present invention can pass through olfactory epithelium cells through nasal mucosa, enter into olfactory and trigeminal nerve surrounding pathways and enter into cerebrum, and at the same time, achieve the effect of repairing nerves of the whole body through peripheral nerve.
[0008] In view of the above, the present invention focuses on the cranial nerves, which are difficult to repair, in order to achieve the effect of making it possible to repair both the central nerves and peripheral nerves in the nervous system.
[0009] The "central nervous system" consists of the brain and spinal cord. In the present invention, the "central nervous system" includes, but is not limited to, the olfactory brain, amygdala, hippocampus, neocortex, lateral ventricle, epithalamus, thalamus, hypothalamus, ventral thalamus, pituitary gland, pineal gland, third ventricle, tectum, cerebral peduncle, pretectal area, aqueduct, pons, cerebellum medulla oblongata, and spinal cord.
[0010] The "peripheral nerves" consist of the somatic nervous system and the autonomic nervous system. In the present invention, the "peripheral nerves" include, but are not limited to, the sensory nerves, motor nerves, cranial nerves, spinal nerves, sympathetic nerves, parasympathetic nerves, and enteric nervous system.
[0011] The present invention provides an isopropyl-D-glucopyranoside derivative having a chemical structure represented by chemical formula (1).
[0012] [ka]
[0013] R1 is a substituted or unsubstituted chemical structure represented by chemical formula (2) or chemical formula (3).
[0014] [ka]
[0015] R2 and R3 are substituted or unsubstituted chemical structures represented by chemical formula (4) or chemical formula (5).
[0016] [ka]
[0017] R4 is hydrogen, deuterium, tritium, a hydroxyl group or a halogen.
[0018] R5 is hydrogen, deuterium, tritium, a hydroxy group, a carbonyl group or a halogen.
[0019] R6 is hydrogen, deuterium, tritium, a hydroxyl group, a carbonyl group or a halogen.
[0020] R7 is hydrogen, deuterium, tritium, a hydroxyl group or a halogen.
[0021] R1" is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium, tritium, or a hydroxy group.
[0022] R2″ is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium, tritium, or a hydroxy group.
[0023] R3″ is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium or tritium.
[0024] R4″ is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium or tritium.
[0025] In some embodiments, the isopropyl-D-glucopyranoside derivatives of the present invention include compounds of the following formula:
[0026] [ka]
[0027] [ka]
[0028] The R1 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium, tritium, or a hydroxyl group.
[0029] The R2 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium, tritium, or a hydroxyl group.
[0030] The R3 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium or tritium.
[0031] The R4 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium or tritium.
[0032] The R5 is hydrogen, deuterium, tritium, a hydroxyl group, a carbonyl group or a halogen.
[0033] The R6 is hydrogen, deuterium, tritium, a hydroxyl group or a halogen.
[0034] The "isopropyl-D-glucopyranoside derivatives" used in the present invention are used for "treatment of nerve damage." In order to allow those skilled in the art to understand the contents of the invention of the present patent application, the present invention uses "Ampelopsisionoside," "Byzantionoside B," and "Roseoside" in the "isopropyl-D-glucopyranoside derivatives" as examples.
[0035] In some embodiments, the compound of the following chemical formula (6) in the isopropyl-D-glucopyranoside derivative of the present invention can be obtained by the following chemical synthesis steps:
[0036] [ka]
[0037] (A) As shown in Flow 1 below, a compound of formula (7) is converted to a compound of formula (8) by a bis-alkylation reaction, an acylation reaction, and an alkyne nucleophilic addition reaction.
[0038] [ka]
[0039] Regarding the substituents of the compound represented by chemical formula (8), R1 may be a methyl group, an ethyl group, a propyl group, a hydrogen, a deuterium, a tritium, or a hydroxy group; R2 may be a methyl group, an ethyl group, a propyl group, a hydrogen, a deuterium, a tritium, or a hydroxy group; R3 may be a methyl group, an ethyl group, a propyl group, a hydrogen, a deuterium, or a tritium; and R4 may be a methyl group, an ethyl group, a propyl group, a hydrogen, a deuterium, or a tritium.
[0040] The bis-alkylation reaction is carried out with an electrophile 1. The electrophile 1 is methyl iodide, ethyl iodide, propyl iodide, MeOTf, EtOTf, PrOTf, propyl bromide / sodium iodide, or dimethyl sulfate. The reagent for the acylation reaction is formaldehyde, acetaldehyde, or propionaldehyde. This intermediate is further subjected to an alkyne nucleophilic addition reaction to obtain compound (8). The reagent for the alkyne nucleophilic addition includes an alkyne having a functional group of R4 and a base. The base includes n-butyl lithium (nBuLi), lithium diisopropylamide (LDA), and lithium bis(trimethylsilyl)amide (LHMDS). The functional group of R4 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium, or tritium.
[0041] (B) As shown in Flow 2 below, the compound represented by chemical formula (8) is converted to the compound represented by chemical formula (9) by an olefination reaction, a reduction reaction, and a deprotection reaction.
[0042] [ka]
[0043] In the olefination reaction, the compound represented by chemical formula (8) is first reacted with the electrophile 2 and an amine-based reagent under low-temperature conditions to produce a compound represented by chemical formula (9). The electrophile 2 is mesyl chloride, tosyl chloride, acetic anhydride, benzoic anhydride, methyl iodide, or dimethyl sulfate. The amine-based reagent is triethylamine, diethylamine, pyridine, pyrrolidine, diisopropyl amine, 2,6-lutidine, or 1,4-diazabicyclo[2.2.2]octane. The low-temperature conditions are at a temperature of -30 to 25°C. After completion, a second base is added to complete the olefination. The second base is potassium tert-butoxide, sodium hydroxide, sodium methoxide, or 1,8-diazabicyclo[5,4,0]undec-7-ene. After completion, a reduction reaction is then carried out. In the reduction reaction, a reducing agent 1 is used as a reducing agent. The reducing agent 1 is lithium aluminum hydride, diisobutyl aluminum hydride (DIBAL), sodium borohydride, sodium triacetoxyborohydride (NaB(OAc) 3H), lithium triethylborohydride, or sodium bis(2-methoxyethoxy)aluminumhydride. The reaction temperature of the reduction reaction is -50 to 25°C. Subsequently, after completion, a deprotection step is performed. In the deprotection step, a deprotection reaction is performed using a deprotection reagent 1 to obtain a compound represented by chemical formula (9). The deprotection reagent 1 is tetrabutyl ammonium fluoride (TBAF), anhydrous hydrofluoric acid-pyridine (HF-py), hydrochloric acid, or potassium tert-butoxide. The reaction temperature of the deprotection reaction is -35 to 25°C.
[0044] (C) As shown in Flow 3 below, a compound represented by formula (9) is coupled to a compound represented by formula (10) via a glycosylation reaction to form a compound represented by formula (11).
[0045] [ka]
[0046] The compound represented by chemical formula (9) is reacted with the sugar-binding reagent 1 by the sugar-binding reaction to obtain a compound represented by chemical formula (10). The sugar-binding reagent 1 is nickel sulfide / silver trifluoromethanesulfonate (NIS / AgOTf), bromosulfophthalein / tri-tert-butylphenol / trifluoromethanesulfonic anhydride (BSP / TTBP / Tf2O), trimethylsilyl trifluoromethanesulfonate / nickel sulfide (TMSOTf / NIS), trimethylsilyl trifluoromethanesulfonate (TMSOTf), silver trifluoromethanesulfonate (AgOTf) or CuOTf. The reaction temperature of the sugar-binding reaction is -78 to 0°C.
[0047] (D) The compound of formula (11) is converted to the compound of formula (6) by deketalization, isomerization, debenzoylation and 1,4-reduction.
[0048] The compound represented by the chemical formula (11) is first subjected to a deketalization and isomerization reaction. The deketalization and isomerization reaction is carried out using Reagent 1. The Reagent 1 is a mixture of an aqueous solution of acetic acid, an aqueous solution of hydrochloric acid, an aqueous solution of trifluoroacetic acid, TsOH and H 2 The debenzoylation reaction is carried out using a debenzoylation reagent. The debenzoylation reagent is, for example, sodium hydroxide, sodium methoxide, sodium ethoxide, potassium hydroxide, potassium methoxide, potassium ethoxide, hydrogen chloride-methanol solution, hydrochloric acid solution, trifluoroacetic acid (TFA) and H 2 O, or an aqueous sulfuric acid solution. Then, the 1,4-reduction reaction is carried out to obtain the compound represented by chemical formula (6). The 1,4-reduction reaction is carried out using a 1,4-reduction reaction reagent. The 1,4-reduction reaction reagent is sodium borohydride, lithium aluminum hydride, sodium triacetoxyborohydride (NaB(OAc) 3 H), NaBCNH 3 , lithium tri-sec-butylborohydride (L-selectride), [CuH(PPh 3 )] 6 , diisobutyl aluminum hydride (DIBAL) or H 2 The reaction temperature of the 1,4-reduction reaction is −78 to 25° C.
[0049] R1 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium, tritium or a hydroxy group.
[0050] R2 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium, tritium or a hydroxy group.
[0051] R3 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium or tritium.
[0052] R4 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium or tritium.
[0053] In some embodiments, the compound represented by the following chemical formula (12) in the isopropyl-D-glucopyranoside derivative of the present invention can be obtained by the following chemical synthesis steps.
[0054] [ka]
[0055] (A) As shown in Flow 4 below, a compound represented by chemical formula (11) is converted into a compound represented by chemical formula (12).
[0056] [ka]
[0057] The conversion includes deprotection of the acetal, isomerization, stereoselective deoxidation, and deprotection of the benzoyl group. The deprotection of the acetal and the isomerization are carried out with an acidic reagent. The acidic reagent is an aqueous solution of acetic acid, an aqueous solution of hydrochloric acid, trifluoroacetic acid (TFA) and H 2 O, TsOH and H 2 The reaction mixture is a mixture of 1,4-dioxane, HCl in 1,4-dioxane, or an aqueous sulfuric acid solution. Then, stereoselective deoxidation is performed using a reducing agent 2 under a first low-temperature condition. The reducing agent 2 is NaBH 4 , LiAlH 4 , sodium triacetoxyborohydride (NaB(OAc) 3 H), NaBCNH 3 , Et 3 SiH / BF 3 -Et 2O, lithium tri-sec-butylborohydride (L-selectride), [CuH(PPh 3 )] 6 Or diisobutylaluminum hydride (DIBAL). The amount of the reducing agent 2 is 0.5, 1.0, 2.0, 3.0, 4.0 or 5.0 equivalents. The temperature of the first low-temperature condition in the stereoselective deoxidation step is −78 to 25° C. Next, the benzoyl group of the intermediate is removed with a deprotection reagent 2 to produce a compound represented by chemical formula (11). The deprotection reagent 2 is NaOH, NaOMe, NaOEt, KOH, KOMe, KOEt, hydrogen chloride-methanol solution, HCl aqueous solution, trifluoroacetic acid (TFA) and H 2 O or H 2 SO 4 It is an aqueous solution.
[0058] R1 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium, tritium or a hydroxy group.
[0059] R2 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium, tritium or a hydroxy group.
[0060] R3 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium or tritium.
[0061] R4 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium or tritium.
[0062] In some embodiments, the compound represented by the following chemical formula (13) in the isopropyl-D-glucopyranoside derivative of the present invention can be obtained by the following chemical synthesis steps.
[0063] [ka]
[0064] (A) As shown in Flow 5 below, a compound represented by chemical formula (12) is converted into a compound represented by chemical formula (13) through a conversion reaction.
[0065] [ka]
[0066] The transformation comprises a regioselective and stereoselective 1,4-reduction / carbonyl reduction. The regioselective and stereoselective 1,4-reduction is carried out at a second low temperature with a reducing agent 3. The reducing agent 3 is NaBH 4 , LiAlH 4 , sodium triacetoxyborohydride (NaB(OAc) 3 H), NaBCNH 3 , lithium tri-sec-butylborohydride (L-selectride), [CuH(PPh 3 )] 6 , DIBAL or H 2 , Pd / C. The equivalent of the reducing agent 3 is 0.5, 1.0, 2.0, 3.0, 4.0 or 5.0 equivalents. The temperature of the second low-temperature conditions in the regioselective and stereoselective 1,4-reduction step is -78 to 25°C.
[0067] R1 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium, tritium or a hydroxy group.
[0068] R2 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium, tritium or a hydroxy group.
[0069] R3 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium or tritium.
[0070] R4 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium or tritium.
[0071] In some embodiments, the compound represented by the following chemical formula (14) in the isopropyl-D-glucopyranoside derivative of the present invention can be obtained by the following chemical synthesis steps.
[0072] [ka]
[0073] (A) Compounds of formula (12) are converted to compounds of formula (14) by selective alkene reduction as shown in Scheme 6 below.
[0074] [ka]
[0075] The selective alkene reduction is carried out using a reducing agent 4. The reducing agent 4 is sodium borohydride, lithium aluminum hydride, sodium triacetoxyborohydride (NaB(OAc) 3 H), NaBCNH 3 , lithium tri-sec-butylborohydride (L-selectride), [CuH(PPh 3 )] 6 , diisobutyl aluminum hydride (DIBAL), H 2 / Pd / C or RhCl(PPH 3 ) 3 / H 2 The reaction temperature of the selective alkene reduction reaction is −78 to 25° C.
[0076] R1 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium, tritium or a hydroxy group.
[0077] R2 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium, tritium or a hydroxy group.
[0078] R3 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium or tritium.
[0079] R4 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium or tritium.
[0080] In some embodiments, the compound represented by the following chemical formula (15) in the isopropyl-D-glucopyranoside derivative of the present invention can be obtained by the following chemical synthesis steps.
[0081] [ka]
[0082] (A) As shown in Flow 7 below, a compound represented by chemical formula (9) is converted to a compound represented by chemical formula (15) by deketalization, isomerization, and debenzoyl protection.
[0083] [ka]
[0084] The compound represented by the chemical formula (9) is first subjected to the deketalization and isomerization reactions. The deketalization and isomerization reactions are carried out using a deketalization and isomerization reaction reagent. The deketalization and isomerization reaction reagents include an aqueous solution of acetic acid, an aqueous solution of hydrochloric acid, an aqueous solution of trifluoroacetic acid, TsOH and H 2 The debenzoylation reaction is carried out using a debenzoylation protection reagent. The debenzoylation protection reagent is sodium hydroxide, sodium methoxide, sodium ethoxide, potassium hydroxide, potassium methoxide, potassium ethoxide, hydrogen chloride-methanol solution, hydrochloric acid solution, trifluoroacetic acid (TFA) and H 2 O, or an aqueous solution of sulfuric acid.
[0085] R1 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium, tritium or a hydroxy group.
[0086] R2 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium, tritium or a hydroxy group.
[0087] R3 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium or tritium.
[0088] R4 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium or tritium.
[0089] In some embodiments, the compound represented by the following chemical formula (16) and the compound represented by the following chemical formula (17) in the isopropyl-D-glucopyranoside derivative of the present invention can be obtained by the following chemical synthesis steps.
[0090] As shown in Flow 8 below, the compound represented by chemical formula (15) is converted into a compound represented by chemical formula (16) and a compound represented by chemical formula (17) by a selective reduction reaction.
[0091] [ka]
[0092] The compound represented by the chemical formula (15) is selectively reduced to obtain a compound represented by the chemical formula (16) and a compound represented by the chemical formula (17) by using a selective reduction reaction reagent. The selective reduction reaction reagent is sodium borohydride, lithium aluminum hydride, sodium triacetoxyborohydride (NaB(OAc) 3 H), NaBCNH 3 , lithium tri-sec-butylborohydride (L-selectride), [CuH(PPh 3 )] 6 , diisobutyl aluminum hydride (DIBAL) or H2 The reaction temperature of the selective reduction reaction is -78 to 25°C.
[0093] R1 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium, tritium or a hydroxy group.
[0094] R2 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium, tritium or a hydroxy group.
[0095] R3 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium or tritium.
[0096] R4 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium or tritium.
[0097] In some embodiments, the isopropyl-D-glucopyranoside derivatives of the present invention have very low toxicity to Neuro2a cells. Effect of the Invention
[0098] The present invention further provides the use of an isopropyl-D-glucopyranoside derivative for promoting nerve repair.
[0099] In some examples, the isopropyl-D-glucopyranoside derivatives alone can promote the regeneration of injured hippocampal neurons and promote nerve regeneration in three-dimensional brain tissue slices, proving that the compounds can effectively promote neuronal regeneration and can be used to repair nerve damage.
[0100] In some embodiments, the isopropyl-D-glucopyranoside derivatives of the present invention can promote neural retinal repair.
[0101] In some embodiments, the isopropyl-D-glucopyranoside derivatives of the present invention, when administered intranasally, can cross the blood-brain barrier of the user and enter the cerebrum, thereby promoting the repair of damaged neurons.
[0102] In some embodiments, the isopropyl-D-glucopyranoside derivatives of the present invention can cross the blood-brain barrier and enter the cerebrum, thereby promoting the repair, regeneration, or increase in the number of brain nerves.
[0103] In some embodiments, the isopropyl-D-glucopyranoside derivatives of the present invention can promote the regeneration of cortical neurons following brain trauma.
[0104] In some embodiments, the effective dose / concentration of the isopropyl-D-glucopyranoside derivative used in the present invention is 9.674 nM to 1342 μM.
[0105] In some embodiments, the isopropyl-D-glucopyranoside derivatives of the present invention have a remarkable effect on nerve repair. The compounds administered intranasally can penetrate the blood-brain barrier and enter the cerebrum, promoting the repair of damaged neurons, promoting the repair, regeneration or increase in the number of cranial nerves, and promoting the regeneration of axons of cortical neurons and hippocampal neurons after brain trauma.
[0106] By referring to the following embodiments, those skilled in the art can easily understand the basic spirit and other objects of the present invention, as well as the technical means and embodiments used in the present invention. [Brief description of the drawings]
[0107] [Figure 1A] FIG. 1A shows the results of a cytotoxicity experiment of the isopropyl-D-glucopyranoside derivative of the present invention. [Figure 1B] FIG. 1B shows the results of a cytotoxicity experiment of the isopropyl-D-glucopyranoside derivative of the present invention. [Figure 1C] FIG. 1C shows the results of a cytotoxicity experiment of the isopropyl-D-glucopyranoside derivative of the present invention. [Diagram 2] FIG. 2 is a flow chart of an in vitro nerve repair test according to the present invention. [Diagram 3] FIG. 3 is a schematic diagram of the calculation of gap closure rate to quantify relative axonal regeneration in the present invention. [Figure 4A] FIG. 4A shows the results of an in vitro neuronal repair experiment on hippocampal neurons using ampelopsicionoside, an isopropyl-D-glucopyranoside derivative of the present invention. [Figure 4B] FIG. 4B shows the results of an in vitro neuronal repair experiment on hippocampal neurons using ampelopsicionoside, an isopropyl-D-glucopyranoside derivative of the present invention. [Diagram 5] FIG. 5 shows the results of an in vitro neuronal repair experiment on cortical neurons using ampelopsicionoside, an isopropyl-D-glucopyranoside derivative of the present invention. [Figure 6] FIG. 6 shows the results of an in vitro neuronal repair experiment on hippocampal neurons using bizanceoside B, which is an isopropyl-D-glucopyranoside derivative of the present invention. [Figure 7] FIG. 7 shows the results of an in vitro neuronal repair experiment on cortical neurons using bizancethionoside B, which is an isopropyl-D-glucopyranoside derivative of the present invention. [Figure 8] FIG. 8 shows the results of an in vitro experiment on neuronal repair in hippocampal neurons using roseoside, which is an isopropyl-D-glucopyranoside derivative of the present invention. [Figure 9]FIG. 9 shows the results of an in vitro neuronal repair experiment on cortical neurons using roseoside, which is an isopropyl-D-glucopyranoside derivative of the present invention. [Figure 10] FIG. 10 is a flow chart of an ex vivo brain tissue slice experiment in the present invention. [Figure 11] FIG. 11 shows the results of an ex vivo three-dimensional brain tissue slice experiment using ampelopsicionoside, an isopropyl-D-glucopyranoside derivative of the present invention. [Figure 12] FIG. 12 shows the results of an ex vivo three-dimensional brain tissue slice experiment using bizanceoside B, an isopropyl-D-glucopyranoside derivative of the present invention. [Figure 13] FIG. 13 shows the results of an ex vivo three-dimensional brain tissue slice experiment using roseoside, an isopropyl-D-glucopyranoside derivative of the present invention. [Figure 14] FIG. 14 shows a flow chart of the controlled cortical impact brain injury model experiment of the present invention, and the results of an experiment on the promotion of motor function recovery in rats after brain injury using ampelopsicionoside, an isopropyl-D-glucopyranoside derivative. [Figure 15] FIG. 15 shows a flow chart of the controlled cortical impact brain injury model experiment of the present invention and the results of an experiment on the promotion of recovery of the ability to explore the environment in rats after brain injury (pressure measurement) using ampelopsicionoside, an isopropyl-D-glucopyranoside derivative. [Figure 16] FIG. 16 is a flow chart of a controlled cortical impact brain trauma model experiment using ampelopsicionoside, which is an isopropyl-D-glucopyranoside derivative of the present invention. [Figure 17] FIG. 17 shows the results of a horizontal bar test in a controlled cortical impact brain trauma model experiment using ampelopsicionoside, an isopropyl-D-glucopyranoside derivative of the present invention. [Figure 18]FIG. 18 is a flow chart showing the promotion of ex vivo retinal neural repair by the isopropyl-D-glucopyranoside derivative of the present invention, bizancethionoside B. [Figure 19] FIG. 19 shows the results of an ex vivo experiment on the promotion of retinal neural repair by bizancethionoside B, which is an isopropyl-D-glucopyranoside derivative of the present invention. [Figure 20] FIG. 20 is a flow chart showing the promotion of ex vivo retinal neural repair by roseoside, an isopropyl-D-glucopyranoside derivative of the present invention. [Figure 21] FIG. 21 shows the results of an ex vivo experiment on the promotion of retinal neural repair by roseoside, which is an isopropyl-D-glucopyranoside derivative of the present invention. [Figure 22] FIG. 22 is a flow chart showing the synthesis of each derivative of isopropyl-D-glucopyranoside according to the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0108] In order to make the contents of the present disclosure more detailed and complete, the following describes the embodiments and specific examples of the present invention. However, this is not the only way to implement or operate the specific examples of the present invention. The embodiments cover the features of several specific examples and the methods and applications for operating these specific examples, but other specific examples can achieve the same or equivalent effects. It should be understood that these examples are for the purpose of explaining the present invention, and do not limit the scope of the present invention. EXAMPLES
[0109] Cytotoxicity experiments of isopropyl-D-glucopyranoside derivatives
[0110] Using the CellTiter-Glo cell viability assay, the toxicity of the isopropyl-D-glucopyranoside derivatives of the present invention, Ampelopsisionoside, Byzantionoside B, and Roseoside, to Neuro2a cells was examined. By measuring the ATP content in the cells using the CellTiter-Glo cell viability assay, it was possible to quantify the cell viability after the addition of the compounds.
[0111] As shown in Figures 1A to 1C, the experimental results show that the IC50 values of ampelopsicionoside, bizanthione B and roseoside for Neuro2a cells were in the range of about 4.175 mM to 32.658 mM. This indicates that the isopropyl-D-glucopyranoside derivatives have very low toxicity to cells. EXAMPLES
[0112] In vitro neuronal repair of hippocampal neurons using ampelopsicionoside, an isopropyl-D-glucopyranoside derivative
[0113] As shown in Figure 2, in this experimental flow, a rat fetus was taken out on the 18th day of pregnancy, and the fetal cerebrum was divided into the cerebral cortex and hippocampus. Next, the cerebral cortex and hippocampus were separated into cortical neurons and hippocampal neurons, and the hippocampal neurons were transferred to a 48-well plate. This day was designated Day In Vitro 0 (DIV0), and at DIV2, cytosine arabinoside (Cytosine beta-D-arabinoside, AraC) was added to inhibit the proliferation of glial cells. At DIV8, the neurons were injured using a micropipette tip, and ampelopsicionoside (concentrations 9.674 nM to 967.4 μM) was added. 0.1% dimethyl sulfoxide (DMSO) was used as the solvent for ampelopsicionoside. 72 hours after the addition of ampelopsicionoside, the state of nerve regeneration was observed by immunofluorescence staining using TUJ1 antibody to label the nerve cells. The experiment was photographed with a Zeiss Observer Z1 microscope.
[0114] As shown in Figure 3, the degree of axon regeneration was quantified from the gap closure rate. The white dotted line is the boundary that was created when nerve cells were injured by rubbing with a micropipette tip, and the black area in the center is the area that was rubbed with the micropipette tip. The regenerated neurites grew from both sides of the dotted line toward the center. For the calculation method, one line was drawn in the gap for every 50 μm of the damaged area to calculate the width of the gap, and after drawing a total of 10 lines, the length of the gap between injured borders (Lg) was calculated as the average. In addition, after a certain period of time, one line was drawn for every 50 μm of the same damaged area, and the length was calculated after connecting the axons that had been extended by regeneration. After drawing the 10 lines, the average length of the gap between regenerated neurons (Ln) was calculated, and the gap closure rate was calculated from (Lg-Ln) / Lg. The scale was set to 100 μm. This experiment was photographed with a Zeiss Observer Z1 microscope.
[0115] As shown in Figure 4A-B, the degree of axon regeneration was quantified from the gap closure rate. The experimental results showed that ampelopsicionoside could effectively promote the growth of hippocampal neurites. EXAMPLES
[0116] Ampelopsicionoside, an isopropyl-D-glucopyranoside derivative, promotes regeneration of injured cortical neurons in vitro
[0117] In this experiment, fetuses of rats on the 18th day of pregnancy were removed, and the fetal cerebrum was divided into the cerebral cortex and hippocampus. The fetal cerebrum was then separated into cortical and hippocampal neurons, and the cortical neurons were transferred to a 48-well plate. This day was designated Day In Vitro 0 (DIV0), and at DIV2, cytosine arabinoside (AraC) was added to inhibit the proliferation of glial cells. At DIV8, neurons were injured using a micropipette tip, and ampelopsicionoside (9.674 nM to 96.74 μM) was added. 0.1% DMSO was used as the solvent control group. All results in the figure are normalized to the DMSO group. 72 hours after the addition of ampelopsicionoside, the neural regeneration status was observed by labeling the neurons with TUJ1 antibody using immunofluorescence staining. This experiment was photographed with a Zeiss Observer Z1 microscope. The scale was set to 100 μm.
[0118] The degree of axon regeneration was quantified by calculating the gap closure rate for 0.1% DMSO, as shown in Figure 5. The area between the two dotted lines in the immunofluorescence images represents the damaged area. The experimental results indicated that ampelopsicionoside could effectively promote the growth of cortical neurites. EXAMPLES
[0119] In vitro neuronal repair of hippocampal neurons using isopropyl-D-glucopyranoside derivative, bisthionoside B
[0120] In this experiment, fetuses of pregnant rats were removed on the 18th day of pregnancy, and the fetal cerebrum was divided into the cerebral cortex and hippocampus. The fetuses were then separated into cortical neurons and hippocampal neurons, and the hippocampal neurons were transferred to a 48-well plate. This day was designated Day In Vitro 0 (DIV0), and at DIV2, cytosine arabinoside (AraC) was added to inhibit the proliferation of glial cells. At DIV8, neurons were injured using a micropipette tip, and bizancenoside B (0.13 μM to 1342 μM) was added. Note that ddH2 The results shown in the figure were compared with those in the control group. 2 The results are normalized to group O. 72 hours after the addition of bisthionoside B, the state of nerve regeneration was observed by labeling nerve cells with TUJ1 antibody using immunofluorescence staining. This experiment was photographed with a Zeiss Observer Z1 microscope. The scale was 100 μm.
[0121] As shown in Figure 6, ddH 2 The degree of axon regeneration was quantified by calculating the gap closure rate relative to ddH. The area between the two dotted lines in the immunofluorescence images represents the damaged area. The dotted line in the lower panel represents the area of injury. 2 It represents group O. The experimental results showed that bizanthione B could effectively promote the proliferation of hippocampal neurites. EXAMPLES
[0122] In vitro neuronal repair of cortical neurons by isopropyl-D-glucopyranoside derivative, bisthionoside B
[0123] In this experiment, a rat fetus was removed on the 18th day of pregnancy, and the fetal cerebrum was divided into the cerebral cortex and hippocampus. Next, the cerebral cortex and hippocampus were separated into cortical neurons and hippocampal neurons, and the cortical neurons were transferred to a 48-well plate. This day was designated Day In Vitro 0 (DIV0), and at DIV2, cytosine arabinoside (AraC) was added to inhibit the proliferation of glial cells. At DIV8, neurons were injured using a micropipette tip, and bizancenoside B (1.34 μM to 26.84 μM) was added. Secondary distilled water (ddH2O) was used for the culture. 2O) was used as a solvent for bisthionoside B. 72 hours after the addition of bisthionoside B, the state of nerve regeneration was observed by labeling nerve cells with TUJ1 antibody using immunofluorescence staining. This experiment was photographed with a Zeiss Observer Z1 microscope. The area between the two dotted lines represents the damaged area.
[0124] The degree of axon regeneration was quantified from the gap closure rate, as shown in Figure 7. The experimental results indicated that bizanthione B could effectively promote the growth of cortical neurites. EXAMPLES
[0125] In vitro neuronal repair of hippocampal neurons using roseoside, an isopropyl-D-glucopyranoside derivative
[0126] In this experiment, fetuses of rats on the 18th day of pregnancy were removed, and the fetal cerebrum was divided into the cerebral cortex and hippocampus. The fetuses were then separated into cortical neurons and hippocampal neurons, and the hippocampal neurons were transferred to a 48-well plate. This day was designated Day In Vitro 0 (DIV0), and at DIV2, cytosine arabinoside (AraC) was added to inhibit the proliferation of glial cells. At DIV8, neurons were injured using a micropipette tip, and roseoside (0.013 μM to 1294 μM) was added. Note that ddH 2 The results shown in the figure were compared with those in the control group. 2 The results are normalized to group O. 72 hours after the addition of roseoside, the state of nerve regeneration was observed by labeling nerve cells with TUJ1 antibody using immunofluorescence staining. This experiment was photographed with a Zeiss Observer Z1 microscope. The scale was 100 μm.
[0127] As shown in Figure 8, ddH 2The degree of axon regeneration was quantified by calculating the gap closure rate relative to ddH. The area between the two dotted lines in the immunofluorescence images represents the damaged area. The dotted line in the lower panel represents the area of injury. 2 It represents group O. The experimental results showed that roseoside could effectively promote the proliferation of hippocampal neurites. EXAMPLES
[0128] In vitro neuronal repair of cortical neurons using roseoside, an isopropyl-D-glucopyranoside derivative
[0129] In this experiment, fetuses of rats on the 18th day of pregnancy were removed, and the fetal cerebrum was divided into the cerebral cortex and hippocampus. The fetuses were then separated into cortical neurons and hippocampal neurons, and the cortical neurons were transferred to a 48-well plate. This day was designated Day In Vitro 0 (DIV0), and at DIV2, cytosine arabinoside (AraC) was added to inhibit the proliferation of glial cells. At DIV8, neurons were injured using a micropipette tip, and roseoside (1.29 μM to 25.88 μM) was added. Note that ddH 2 O was used as the solvent for roseoside. 72 hours after the addition of roseoside, the state of nerve regeneration was observed by labeling neurons with TUJ1 antibody using immunofluorescence staining. This experiment was photographed with a Zeiss Observer Z1 microscope.
[0130] The degree of axon regeneration was quantified from the gap closure rate, as shown in Figure 9. The experimental results indicated that roseoside could effectively promote the regeneration of cortical axons. EXAMPLES
[0131] Ex vivo 3D brain tissue slice experiments with ampelopsicionoside, an isopropyl-D-glucopyranoside derivative
[0132] As shown in Figure 10, in the flow of this experiment, first, the brain of a fetal rat was removed and embedded in low-melting-point agarose gel, and then sliced into tissue sections 350 μm thick using a Leica microtome VT100. Next, the brain sections were scratched with a scalpel and then cultured and stored in ddH 2 O or ampelopsicionoside was added daily. After 96 hours of culture, the neurons were labeled with TUJ1 antibody, the glial cells were labeled with GFAP antibody, and the cell nuclei were labeled with DAPI reagent by fluorescent immunostaining. The scale of this experiment was 100 μm. The experiment was photographed using a Zeiss LSM800 confocal microscope.
[0133] As shown in Figure 11, the white dotted line indicates the incision made with a scalpel, and the right side of the dotted line is the newly generated axon. This experiment demonstrated that ampelopsicionoside has the effect of promoting nerve regeneration. EXAMPLES
[0134] Ex vivo brain tissue slice experiments with isopropyl-D-glucopyranoside derivative, bisthionoside B
[0135] As shown in Figure 10, in the flow of this experiment, first, the brain of a fetal rat was removed and embedded in low-melting-point agarose gel, and then sliced into tissue sections 350 μm thick using a Leica microtome VT100. Next, the brain sections were scratched with a scalpel and then cultured and stored in ddH 2 O or bisthionoside B was added daily. After 96 hours of culture, the neurons were labeled with TUJ1 antibody, the glial cells were labeled with GFAP antibody, and the cell nuclei were labeled with DAPI reagent by fluorescent immunostaining. The scale of this experiment was 100 μm. In addition, this experiment was photographed using a Zeiss LSM800 confocal microscope.
[0136] As shown in Figure 12, the white dotted line indicates the incision made with a scalpel, and the right side of the dotted line is the newly generated neurite. This experiment demonstrated that bizanthione B has the effect of promoting nerve regeneration. EXAMPLES
[0137] Ex vivo brain tissue slice experiments with roseoside, an isopropyl-D-glucopyranoside derivative
[0138] As shown in Figure 10, in the flow of this experiment, first, the brain of a fetal rat was removed and embedded in low-melting-point agarose gel, and then sliced into tissue sections 350 μm thick using a Leica microtome VT100. Next, the brain sections were scratched with a scalpel and then cultured and stored in ddH 2 O or roseoside was added every day. After 96 hours of culture, the neurons were labeled with TUJ1 antibody, the glial cells were labeled with GFAP antibody, and the cell nuclei were labeled with DAPI reagent by fluorescent immunostaining. The scale of this experiment was 100 μm. In addition, this experiment was photographed using a Zeiss LSM800 confocal microscope.
[0139] As shown in Figure 13, the white dotted line indicates the incision made with a scalpel, and the right side of the dotted line is the newly generated neurite. This experiment demonstrated that roseoside has the effect of promoting nerve regeneration. EXAMPLES
[0140] Ampelopsicionoside, an isopropyl-D-glucopyranoside derivative, enhances motor recovery after traumatic brain injury in rats
[0141] In this experiment, mice were subjected to craniotomy without brain injury, brain injury, and daily administration of 14 μg / kg of ampelopsicionoside after brain injury. The motor abilities were measured using an open field test and compared 1 or 5 days after (1 day post injury: 1 dpi, 5 day post injury: 5 dpi). The experimental model used in this experiment is shown in Figure 14. At 0 dpi, mice were brain-injured using a controlled cortical impact brain injury model, and at 0, 2, 4, 6, 8, 10, and 12 dpi (day post injury), 14 μg / kg of ampelopsicionoside was administered intranasally.
[0142] As shown in Figure 14, part A is the test in which a mouse was placed in a large white acrylic box divided into four equal parts and allowed to move freely for 5 minutes. The mouse's movement was recorded by a Microsoft LifeCam Cinema camera for 5 minutes and analyzed by Anubis track software.
[0143] As shown in Figure 14, part B shows that the movement path length of the ampelopsicionoside group and the uninjured group was almost the same, while the untreated brain-injured group only had half the path length, which revealed that ampelopsicionoside, an isopropyl-D-glucopyranoside derivative of the present invention, has the effect of promoting the recovery of motor ability in rats after brain trauma. EXAMPLES
[0144] Ampelopsicionoside, an isopropyl-D-glucopyranoside derivative, enhances recovery of exploratory ability in rats after traumatic brain injury
[0145] In this experiment, mice were subjected to craniotomy without brain injury, brain injury, and administration of 14 μg / kg of ampelopsicionoside after brain injury. Five days after injury (5 days post injury: 5 dpi), the exploration ability in the area and the time spent in the central open area were measured by open field test. The experimental model of this experiment is shown in Figure 17. At 0 dpi, mice were brain injured using a controlled cortical impact brain trauma model, and at 0, 2, 4, 6, 8, 10, and 12 dpi (days post injury), 14 μg / kg of ampelopsicionoside was administered via nasal administration.
[0146] As shown in Figure 15, part A is the test in which a mouse was placed in a large white acrylic box divided into four equal parts and allowed to move freely for 5 minutes. The mouse's movement was recorded by a Microsoft LifeCam Cinema camera for 5 minutes and analyzed by Anubis track software.
[0147] As shown in Figure 15, part B shows that the ampelopsicionoside group and the uninjured group spent a long time in the central area, while the untreated brain injury group hardly moved in the central area. Combining Figure 15, it is clear that ampelopsicionoside, which is the isopropyl-D-glucopyranoside derivative of the present invention, has the effect of promoting the recovery of exploration ability of rats after brain trauma. EXAMPLES
[0148] Ampelopsicionoside, an isopropyl-D-glucopyranoside derivative, promotes recovery of motor coordination after traumatic brain injury in rats
[0149] In the horizontal bar experiment, a mouse was placed on a brass bar 38 cm long and 2 mm, 4 mm, or 6 mm in diameter, located 49 cm above the ground, and was allowed to grasp the brass bar with its front paws. The time the mouse spent on the brass bar was calculated, and the motor coordination ability of the mouse was evaluated based on whether it reached the platform at the end of the brass bar or not. The evaluation criteria were 1 point for 1-5 seconds, 2 points for 5-10 seconds, 3 points for 10-20 seconds, 4 points for 20-30 seconds, and 5 points for 30 seconds or more or reaching the platform.
[0150] As shown in Figure 16, the experimental model of this experiment was pre-trained at -5, -3, and -1 dpi (day post injury) (5 days, 3 days, and 1 day before brain injury), respectively. At 0 dpi, mice were brain-injured using a controlled cortical impact model, and 14 μg / kg or 140 μg / kg of ampelopsicionoside was administered via the nasal cavity at 0, 2, 4, 6, 8, 10, and 12 dpi. Horizontal bar experiments were also performed at 1, 3, 6, 10, and 13 dpi.
[0151] As shown in Figure 17, after brain injury, 2 In the group administered only 1,0-dichlorophenylalanine (O), a loss of motor coordination was observed, whereas in the group administered ampelopsicionoside, motor coordination was similar to that of the sham group, indicating that the recovery of motor coordination was clearly promoted. EXAMPLES
[0152] Bisantienoside B, an isopropyl-D-glucopyranoside derivative, promotes ex vivo retinal neural repair
[0153] The experimental design and flow are shown in Figure 18. Retinal explants were extracted from 8-day-old C57BL / 6 mice. After sacrifice, the eyes were removed, and the eyeballs and retinas were separated using tweezers and microscissors, and the vitreous was removed. Finally, the isolated retina was divided into four pieces, and the tissue edges were trimmed and damaged using microscissors. Each piece was cultured on an 18 mm circular glass plate, then placed in a 12-well plate and placed in an incubator at 5% CO 2 The retinal tissues were cultured at 35°C for 5 days. The culture medium was replaced with fresh medium every day, and 13.5μM or 135μM of bisthionoside B was added. After the retinal tissues were cultured for 5 days, they were fixed at room temperature for 1 hour using a mixture of 0.1% glutaraldehyde solution and 4% paraformaldehyde. They were then stained with the primary antibodies axonal marker beta-III-tubulin (TUJ1) and DAPI to label the neurons and cell nuclei, and photographed with a super-resolution upright confocal microscope (LSM-800, Carl Zeiss). The tissue boundary was selected using the image analysis program ImageJ to calculate the perimeter and the area of nerve fibers outside the tissue. The nerve fiber area was divided by the perimeter of the tissue boundary to calculate the nerve fiber length per perimeter.
[0154] As shown in FIG. 19, after retinal tissue damage, the group administered with bizanthione B had a significantly higher retinal function than the group administered with water (ddH 2 O) alone had a clear post-injury recovery effect. EXAMPLES
[0155] Roseoside, an isopropyl-D-glucopyranoside derivative, promotes ex vivo retinal neural repair
[0156] The experimental design and flow are shown in Figure 20. Retinal explants were extracted from 8-day-old C57BL / 6 mice. After sacrifice, the eyes were removed, and the eyeballs and retinas were separated with tweezers and microscissors, and the vitreous was removed. Finally, the isolated retina was divided into 4 pieces, and the tissue edges were trimmed and damaged with microscissors. Each piece was cultured on an 18 mm circular glass plate, then placed in a 12-well plate and placed in an incubator with 5% CO 2 The retinal tissues were cultured at 35°C for 5 days. The culture medium was replaced with fresh medium every day, and roseoside (13 μM or 130 μM) was added. After the retinal tissues were cultured for 5 days, they were fixed at room temperature for 1 hour using a mixture of 0.1% glutaraldehyde and 4% paraformaldehyde. They were then stained with the primary antibodies axonal marker beta-III-tubulin (TUJ1) and DAPI to label the neurons and cell nuclei, and photographed with a super-resolution upright confocal microscope (LSM-800, Carl Zeiss). The tissue boundary was selected using the image analysis program ImageJ to calculate the perimeter and the area of nerve fibers outside the tissue. The nerve fiber area was divided by the perimeter of the tissue boundary to calculate the nerve fiber length per perimeter.
[0157] As shown in FIG. 21, after retinal tissue damage, the roseoside-administered group showed a significantly increased 2 O) alone had a clear post-injury recovery effect. EXAMPLES
[0158] Sequential steps in the synthesis of isopropyl-D-glucopyranoside derivatives
[0159] The sequential steps of synthesizing the isopropyl-D-glucopyranoside derivative in the present invention were as follows:
[0160] [ka]
[0161] The above experimental data are preliminary experimental results obtained under specific conditions, which are merely intended to facilitate understanding or reference of the technical content of the present invention, and other related experiments need to be conducted. The experimental data and results are not intended to limit the scope of the present invention.
[0162] The above preferred embodiments are merely illustrative of the present invention and its technical features, and the technology of the embodiments may be appropriately implemented by various substantially equivalent modifications and / or replacements. Therefore, the scope of the present invention is subject to the scope defined in the claims.
Claims
1. The chemical structural formula is as shown in formula (1), 【Chemistry 1】 R1 is a substituted or unsubstituted structure of formula (2) or formula (3), 【Chemistry 2】 R2 and R3 are substituted or unsubstituted structures of formula (4) or formula (5); 【Chemistry 3】 R4 is hydrogen, deuterium, tritium, a hydroxyl group or a halogen; R5 is hydrogen, deuterium, tritium, a hydroxyl group, a carbonyl group or a halogen; R6 is hydrogen, deuterium, tritium, a hydroxyl group, a carbonyl group or a halogen; R7 is hydrogen, deuterium, tritium, a hydroxyl group, a carbonyl group or a halogen; R1″ is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium, tritium or a hydroxyl group; R2″ is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium, tritium or a hydroxyl group; R3″ is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium or tritium; An isopropyl-D-glucopyranoside derivative, wherein R4" is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium or tritium.
2. When R1 is represented by chemical formula (2), 【Chemistry 4】 R2 and R3 are substituted or unsubstituted structures of chemical formula (4) or chemical formula (5), 【Chemistry 5】 R4 is hydrogen, deuterium, tritium, a hydroxyl group or a halogen; R5 is hydrogen, deuterium, tritium, a hydroxyl group, a carbonyl group, or a halogen; R6 is hydrogen, deuterium, tritium, a hydroxyl group, a carbonyl group, or a halogen; R7 is hydrogen, deuterium, tritium, a hydroxyl group or a halogen; R1″ is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium, tritium or a hydroxyl group; R2″ is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium, tritium or a hydroxyl group; R3″ is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium or tritium; The isopropyl-D-glucopyranoside derivative according to claim 1, wherein R4″ is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium or tritium.
3. When R1 is represented by chemical formula (3), 【Chemistry 6】 R2 and R3 are substituted or unsubstituted structures of chemical formula (4) or chemical formula (5), 【Chemistry 7】 R4 is hydrogen, deuterium, tritium, a hydroxyl group or a halogen; R5 is hydrogen, deuterium, tritium, a hydroxyl group, a carbonyl group, or a halogen; R6 is hydrogen, deuterium, tritium, a hydroxyl group, a carbonyl group, or a halogen; R7 is hydrogen, deuterium, tritium, a hydroxyl group or a halogen; R1″ is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium, tritium or a hydroxyl group; R2″ is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium, tritium or a hydroxyl group; R3″ is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium or tritium; The isopropyl-D-glucopyranoside derivative according to claim 1, wherein R4″ is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium or tritium.
4. The derivatives include compounds of the formula: 【Chemistry 8】 【Chemistry 9】 R1 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium, tritium, or a hydroxyl group; R2 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium, tritium, or a hydroxyl group; R3 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium or tritium; R4 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium or tritium; R5 is hydrogen, deuterium, tritium, a hydroxyl group, a carbonyl group, or a halogen; 2. The isopropyl-D-glucopyranoside derivative according to claim 1, wherein R6 is hydrogen, deuterium, tritium, a hydroxyl group or a halogen.
5. A method for producing an isopropyl-D-glucopyranoside derivative represented by chemical formula (6), 【Chemistry 10】 (A) converting a compound represented by chemical formula (7) into a compound represented by chemical formula (8) by a bisalkylation reaction, an acylation reaction, and an alkyne nucleophilic addition reaction; 【Chemistry 11】 R1 is a methyl group, an ethyl group, a propyl group, a hydrogen, a deuterium, a tritium or a hydroxy group; R2 is a methyl group, an ethyl group, a propyl group, a hydrogen, a deuterium, a tritium or a hydroxy group; R3 is a methyl group, an ethyl group, a propyl group, a hydrogen, a deuterium, a tritium or a hydroxy group; R4 is a methyl group, an ethyl group, a propyl group, a hydrogen, a deuterium, or a tritium; the bisalkylation reaction is carried out with an electrophile 1; the electrophile 1 is methyl iodide, ethyl iodide, propyl iodide, MeOTf, EtOTf, PrOTf, propyl bromide / iodide, the reagent for the acylation reaction includes formaldehyde, acetaldehyde, or propionaldehyde, and this intermediate is further subjected to an alkyne nucleophilic addition reaction to obtain compound (8), the reagent for the alkyne nucleophilic addition includes an alkyne having a functional group R4 and a base, and the base includes n-butyl lithium (nBuLi), lithium diisopropylamide (LDA), or lithium bis(trimethylsilyl)amide (LHMDS), and the functional group R4 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium, or tritium; (B) converting the compound represented by formula (8) into a compound represented by formula (9) by an olefination reaction, a reduction reaction, and a deprotection reaction; 【Chemistry 12】 In the olefination reaction, the compound represented by the chemical formula (8) is first reacted with an electrophile 2 and an amine-based reagent under low temperature conditions to produce a compound represented by the chemical formula (9). The electrophile 2 is selected from mesyl chloride, tosyl chloride, acetic anhydride, benzoic anhydride, methyl iodide, and dimethyl sulfate, and the amine-based reagent is selected from triethylamine, diethylamine, pyridine, pyrrolidine, diisopropylamine, and ethyldisiopropylamine. amine, 2,6-lutidine, or 1,4-diazabicyclo[2.2.2]octane is selected, the low temperature condition is −30 to 25° C., and then, after completion, a second base is added to complete the olefination, the second base is potassium tert-butoxide, sodium hydroxide, sodium methoxide, or 1,8-diazabicyclo[5,4,0]undec-7-ene, and then, after completion, a reduction reaction is performed, and in the reduction reaction, a reducing agent 1 is used as a reducing agent, and the reducing agent 1 is lithium aluminum hydride, diisobutyl aluminum hydride, hydride (DIBAL)), sodium borohydride, sodium triacetoxyborohydride (NaB(OAc) 3 H), lithium triethylborohydride, or sodium bis(2-methoxyethoxy)aluminumhydride, the reaction temperature of the reduction reaction is −50 to 25° C., and then, after completion, a deprotection step is performed, in which a deprotection reaction is performed using a deprotection reagent 1 to obtain a compound represented by chemical formula (9), the deprotection reagent 1 being tetrabutyl ammonium fluoride (TBAF), anhydrous hydrofluoric acid-pyridine (HF-py), hydrochloric acid, or potassium tert-butoxide, the reaction temperature of the deprotection reaction is −35 to 25° C., (C) coupling a compound represented by formula (9) to a compound represented by formula (10) via a glycosylation reaction to form a compound represented by formula (11); 【Chemistry 13】 The compound represented by the chemical formula (9) is subjected to the sugar-binding reaction using a sugar-binding reagent 1 to obtain a compound represented by the chemical formula (11), the sugar-binding reagent 1 being nickel sulfide / silver trifluoromethanesulfonate (NIS / AgOTf), bromosulfophthalein / tri-tert-butylphenol / trifluoromethanesulfonic anhydride (BSP / TTBP / TfO), trimethylsilyl trifluoromethanesulfonate / nickel sulfide (TMSOTf / NIS), trimethylsilyl trifluoromethanesulfonate (TMSOTf), silver trifluoromethanesulfonate (AgOTf) or CuOTf, and the reaction temperature of the sugar-binding reaction is −78 to 0° C., (D) converting the compound represented by the chemical formula (11) into a compound represented by the chemical formula (6) by deketalization, isomerization, debenzoylation and 1,4-reduction reactions; The compound represented by the chemical formula (11) is first subjected to a deketalization and isomerization reaction. The deketalization and isomerization reaction is carried out using Reagent 1, which is an aqueous solution of acetic acid, an aqueous solution of hydrochloric acid, an aqueous solution of trifluoroacetic acid, TsOH and H 2 The debenzoylation is carried out using a debenzoylation reagent, which may be, for example, sodium hydroxide, sodium methoxide, sodium ethoxide, potassium hydroxide, potassium methoxide, potassium ethoxide, hydrogen chloride-methanol solution, hydrochloric acid solution, trifluoroacetic acid (TFA) and H 2 0, or sulfuric acid aqueous solution, followed by 1,4-reduction reaction to obtain the target compound of formula (6), the 1,4-reduction reaction being carried out with a 1,4-reduction reaction reagent, the 1,4-reduction reaction reagent being sodium borohydride, lithium aluminum hydride, sodium triacetoxyborohydride (NaB(OAc) 3 H), NaBCNH 3 , L-selectride (lithium tri-sec-butylborohydride), [CuH(PPh 3 ) ] 6 , diisobutyl aluminum hydride (DIBAL) or H 2 / Pd / C, and the reaction temperature of the 1,4-reduction reaction is −78 to 25° C.; R1 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium, tritium or a hydroxyl group; R2 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium, tritium or a hydroxyl group; R3 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium or tritium; R4 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium or tritium; A method for producing the same, comprising the step of synthesizing
6. After the step (B), 【Chemistry 14】 (B1) converting the compound represented by the chemical formula (9) into a compound represented by the chemical formula (15) by carrying out deketalization, isomerization, and debenzoyl protection reactions; 【Chemistry 15】 The compound represented by the chemical formula (9) is first subjected to a deketalization and isomerization reaction, and the deketalization and isomerization reactions are carried out using a deketalization and isomerization reaction reagent, and the deketalization and isomerization reaction reagent is an aqueous solution of acetic acid, an aqueous solution of hydrochloric acid, an aqueous solution of trifluoroacetic acid, TsOH and H 2 The debenzoylation reaction is carried out using a debenzoylation reaction reagent, which may be, for example, sodium hydroxide, sodium methoxide, sodium ethoxide, potassium hydroxide, potassium methoxide, potassium ethoxide, hydrogen chloride-methanol solution, hydrochloric acid solution, trifluoroacetic acid (TFA) and H 2 O, or an aqueous solution of hydrochloric acid; R1 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium, tritium or a hydroxyl group; R2 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium, tritium or a hydroxyl group; R3 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium or tritium; R4 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium or tritium; The method for producing the isopropyl-D-glucopyranoside derivative represented by the chemical formula (6) according to claim 5, which may comprise a synthesis step of:
7. After the above-mentioned manufacturing method, 【Chemistry 16】 (B2) converting the compound represented by chemical formula (15) into a compound represented by chemical formula (16) and a compound represented by chemical formula (17) by a selective reduction reaction; 【Chemistry 17】 The compound represented by the chemical formula (15) is selectively reduced using a selective reduction reagent to obtain a compound represented by the chemical formula (16) and a compound represented by the chemical formula (17). The selective reduction reagent is, for example, sodium borohydride, lithium aluminum hydride, or sodium triacetoxyborohydride (NaB(OAc)). 3 H), NaBCNH 3 , lithium tri-sec-butylborohydride (L-selectride), [CuH(PPh 3 ) ] 6 , diisobutyl aluminum hydride (DIBAL) or H 2 / Pd / C, and the reaction temperature of the selective reduction reaction is −78 to 25° C.; R1 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium, tritium or a hydroxyl group; R2 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium, tritium or a hydroxyl group; R3 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium or tritium; R4 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium or tritium; A method for producing an isopropyl-D-glucopyranoside derivative, which is a compound represented by chemical formula (6) according to claim 6, comprising the step of:
8. A method for producing an isopropyl-D-glucopyranoside derivative, which is a compound represented by chemical formula (12), comprising the steps of: 【Chemistry 18】 (A) converting a compound represented by chemical formula (11) into a compound represented by chemical formula (12) by a conversion reaction; 【Chemistry 19】 The conversion reaction includes deprotection of the acetal, isomerization, stereoselective deoxidation, and deprotection of the benzoyl group, and the deprotection of the acetal and the isomerization are carried out with an acidic reagent, which may be an aqueous solution of acetic acid, an aqueous solution of hydrochloric acid, or an aqueous solution of trifluoroacetic acid (TFA) and H. 2 O, TsOH and H 2 The first low-temperature condition is a mixed solution of 1,4-dioxane, 1,4-dioxane, 1,2 ... 4 , LiAlH 4 , sodium triacetoxyborohydride (NaB(OAc) 3 H), NaBCNH 3 , Et 3 SiH / BF 3 -Et 2 O, lithium tri-sec-butylborohydride (L-selectride), [CuH(PPh 3 ) ] 6 or diisobutylaluminum hydride (DIBAL), the amount of the reducing agent 2 is 0.5, 1.0, 2.0, 3.0, 4.0 or 5.0 equivalents, the temperature of the first low-temperature condition in the stereoselective deoxidation step is −78 to 25° C., and then the benzoyl group of the intermediate is removed with a deprotection reagent 2 to produce a compound represented by chemical formula (11), the deprotection reagent 2 being NaOH, NaOMe, NaOEt, KOH, KOMe, KOEt, hydrogen chloride-methanol solution, aqueous HCl solution, trifluoroacetic acid (TFA) and H 2 O or H 2 SO 4 It is an aqueous solution, R1 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium, tritium or a hydroxyl group; R2 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium, tritium or a hydroxyl group; R3 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium or tritium; R4 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium or tritium; A method for producing the same, comprising the step of synthesizing
9. Furthermore, 【Chemistry 20】 (B) converting the compound represented by chemical formula (12) into a compound represented by chemical formula (13) by a conversion reaction; 【Chemistry 21】 The conversion reaction includes a regioselective and stereoselective 1,4-reduction / carbonyl reduction step, the regioselective and stereoselective 1,4-reduction / carbonyl reduction step is carried out under a second low-temperature condition by a reducing agent 3, the reducing agent 3 being NaBH 4 , LiAlH 4 , sodium triacetoxyborohydride (NaB(OAc) 3 H), NaBCNH 3 , lithium tri-sec-butylborohydride (L-selectride), [CuH(PPh 3 ) ] 6 , DIBAL or H 2 / Pd / C, and the equivalent of the reducing agent 3 is 0.5, 1.0, 2.0, 3.0, 4.0 or 5.0 equivalents, and the temperature of the second low-temperature condition in the regioselective and stereoselective 1,4-reduction / carbonyl reduction step is −78 to 25° C.; R1 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium, tritium or a hydroxyl group; R2 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium, tritium or a hydroxyl group; R3 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium or tritium; R4 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium or tritium; A method for producing an isopropyl-D-glucopyranoside derivative represented by the chemical formula (12) according to claim 8, comprising the step of:
10. Furthermore, 【Chemical 22】 (A) converting a compound represented by chemical formula (12) to a compound represented by chemical formula (14) by a selective alkene reduction reaction; 【Chemistry 23】 The selective alkene reduction reaction is carried out using a reducing agent 4, which is sodium borohydride, lithium aluminum hydride, sodium triacetoxyborohydride (NaB(OAc) 3 H), NaBCNH 3 , lithium tri-sec-butylborohydride (L-selectride), [CuH(PPh 3 ) ] 6 , diisobutyl aluminum hydride (DIBAL), H 2 / Pd / C or RhCl(PPH 3 ) 3 / H 2 and the reaction temperature of the selective alkene reduction reaction is −78 to 25° C.; R1 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium, tritium or a hydroxyl group; R2 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium, tritium or a hydroxyl group; R3 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium or tritium; R4 is a methyl group, an ethyl group, a propyl group, hydrogen, deuterium or tritium; A method for producing an isopropyl-D-glucopyranoside derivative, which is a compound represented by chemical formula (12) according to claim 8, comprising the steps of:
11. 2. Use of the isopropyl-D-glucopyranoside derivative according to claim 1 for the manufacture of a medicament for treating nerve damage.
12. The use of an isopropyl-D-glucopyranoside derivative for the manufacture of a medicament for treating nerve damage according to claim 11, characterized in that the nerve damage is central or peripheral nerve damage.
13. The use of an isopropyl-D-glucopyranoside derivative for the manufacture of a medicament for treating nerve damage according to claim 11, characterized in that the nerve damage is neuronal damage.
14. The use of an isopropyl-D-glucopyranoside derivative for the manufacture of a medicament for treating nerve damage according to claim 11, wherein the nerve damage is damage to cortical neurons or hippocampal neurons.
15. The use of an isopropyl-D-glucopyranoside derivative for the manufacture of a medicament for treating nerve damage according to claim 11, characterized in that the treatment is nerve regeneration, increase in nerve number, or nerve repair.
16. The use of isopropyl-D-glucopyranoside derivatives for the manufacture of a medicament for treating nerve damage according to claim 11, characterized in that the isopropyl-D-glucopyranoside derivatives pass through the blood-brain barrier and enter the cerebrum.
17. The use of isopropyl-D-glucopyranoside derivatives for the manufacture of a medicament for treating nerve damage according to claim 11, characterized in that the effective dose of the isopropyl-D-glucopyranoside derivatives is 9.674 nM to 1342 μM.
Citation Information
Patent Citations
Synthesis method for alpha-ionol glucoside, and application of alpha-ionol glucoside to flavoring of cigarettes
CN102617659A
